The aim of this study was to investigate the role of telomerase function on the chemosensitivity of melanoma cells. To this end, ecteinascidin-743 (ET-743) and cisplatin [cis-diamminedichloroplatinum(II) (CDDP)], two DNA-interacting drugs that invariably cause an arrest in the G 2 /M phase, and 1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic acid (LND), a mitochondria-targeting drug inducing a G 1 block, were used. As experimental model, human melanoma clones showing reduced human telomerase reverse transcriptase (hTERT) expression and telomerase activity and characterized by telomere dysfunction were used. Reconstitution of telomerase activity by exogenous hTERT expression improved telomere function and reduced the sensitivity to CDDP and ET-743 without affecting LND susceptibility. The decreased sensitivity to CDDP and ET-743 was mainly caused by the ability of cells to recover from drug-induced damage, evaluated in terms of both chromosomal lesions and cell survival. The ability of hTERT-reconstituted cells to recover from drug-induced damage was attributable to the restoration of cell cycle progression. In fact, the cells without hTERT restoration remained for a prolonged time in the G 2 /M phase, and this cell cycle alteration made irreversible the druginduced S-G 2 /M block and led to the activation of apoptotic program. On the contrary, the hTERT-reconstituted cells progressed quickly through the cell cycle, thus acquiring the capacity to recover from drug-induced block and to protect themselves from the G 2 /M phase-specific drug-triggered apoptosis.
Major obstacles for anticancer chemotherapy are the cytotoxicity of anticancer agents to normal cells and the occurrence of resistant tumor cells to chemotherapeutic agents. Therefore, new chemotherapeutic strategies, which could reduce the cytotoxicity of normal cells and reverse chemoresistance of tumor cells, represent an important goal for the development of selective cancer therapies. Telomerase activity has been found in almost all tumors but not in adjacent normal cells (Shay and Bacchetti, 1997) . The most prominent hypothesis is that the maintenance of telomere stability is required for long-term proliferation of tumors. Therefore, telomerase has become a target for the development of new anticancer therapeutic agents.
The relationship between telomerase and the vulnerability to drug-induced apoptosis is poorly understood. Antisense inhibition of telomerase increases the susceptibility of glioblastoma cells to CDDP-induced apoptosis (Kondo et al., 1998) and enhances apoptosis in pheochromocytoma cells induced by a variety of stimuli (Fu et al., 1999) . Similarly, telomerase inhibition by ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to topoisomerase inhibitors through the activation of the apoptotic program (Ludwig et al., 2001) . These findings suggest a protective role of telomerase against drug-induced apoptotic cell death. Recently, a fast-increasing number of articles seem to indicate that the simple inhibition of telomerase may not result in the anticancer effect (Bearss et al., 2000) . Therefore, although telomerase may not be a universal target for cancer therapy, targeting the telomere maintenance mechanisms could be important for future successful therapeutic anticancer strategies. In this context, by using telomerase-deficient mouse, other studies have demonstrated that telomere dysfunction, rather than telomerase per se, is the principal determinant governing chemosensitivity against agents that induce double-strand DNA breaks (Wong et al., 2000; Lee et al., 2001 ). The present study examines the impact of telomerase function on the sensitivity of melanoma cells to ET-743, a novel marine natural compound that shows a good activity against a variety of tumors (Izbicka et al., 1998; Valoti et al., 1998; Villalona-Calero et al., 2002) ; CDDP, one of the most effective and broadly used anticancer drugs; and LND, a dichlorinated derivative of indazole-3-carboxylic acid, which plays a significant role in reversing or overcoming multidrug resistance (Citro et al., 1991; Silvestrini et al., 1992) . CDDP and ET-743 are DNA-interacting drugs that cause an arrest in the G 2 /M phase (Sorenson and Eastman, 1988; Takebayashi et al., 2001a; Gajate et al., 2002) , whereas LND is a mitochondriatargeting drug inducing a G 1 block (Del Bufalo et al., 1996) . Unlike CDDP and LND, the mechanism of action of is not yet fully elucidated. It binds to guanines at the N2 position in the minor groove (Pommier et al., 1996) , and its cytotoxic effect and cell cycle perturbation (Erba et al., 2001 ) seem related to an alteration of the transcription regulation that occurs in a promoter-dependent fashion (Jin et al., 2000; Minuzzo et al., 2000) . Moreover, cells with mismatch repair defects, which are tolerant to some alkylating agents and to CDDP, are sensitive to ET-743, whereas cells deficient in transcription-coupled nucleotide excision repair, which are very sensitive to CDDP, are resistant to ET-743 (Damia et al., 1996; Takebayashi et al., 2001b) .
We demonstrate here that the reconstitution of telomerase activity, by exogenous hTERT expression, improved telomere function and decreased sensitivity to CDDP and ET-743 without affecting LND susceptibility. The reduced drug sensitivity was caused by the ability of hTERT to modify cellcycle progression, enabling the cells to recover from druginduced G 2 /M block and consequently protecting them from apoptosis.
Materials and Methods
Cells and Culture Conditions. MAS51 and MAS53 c-Myc lowexpressing clones were previously obtained by transfecting the M14 human melanoma line with an expression vector carrying the exon 2 ϩ exon 3 of c-myc cDNA cloned in antisense orientation (Biroccio et al., 2001) . The c-Myc low-expressing clones were then infected with retroviruses encoding hTERT (ϩhTERT cells) or the gene for the puromycin resistance only (ϪhTERT cells) and used after 14 and 35 population doublings (PD), corresponding to the second and fifth culture passages, respectively, after infection (Biroccio et al., 2002) .
The ϪhTERT and ϩhTERT cells were grown at 37°C (5% CO 2 /95% air atmosphere) in RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf serum, 2 mM L-glutamin, and antibiotics and containing neomycin (0.8 mg/ml; Invitrogen) and puromycin (0.5 g/ml; Sigma, Milan, Italy).
Treatments and Clonogenic Assay. Clinical grade CDDP, ET-743, and LND were obtained from Pharmacia (Milan, Italy), PharmaMar (Tres Cantos, Madrid, Spain), and Angelini (Rome, Italy), respectively. Drug dilutions were freshly prepared before each experiment. Cells were seeded in 60-mm Petri dishes (Nunc-Mascia Brunelli, Milan, Italy) at a density of 2 ϫ 10 5 cells/dish. Cells were exposed to different doses of CDDP (ranging from 0.3 to 16 M) for 2 h, ET-743 (ranging from 1 to 50 nM) for 1 h, and LND (ranging from 0.07 to 0.6 mM) for 24 h, and the analysis was performed at the end of treatments. The doses of CDDP and ET-743 that inhibit cell survival by approximately 50% (IC 50 ) in all the cellular lines were used as equitoxic doses. In particular, we used the doses of 7 M CDDP and 20 nM of ET-743 for the treatment of M14 and ϩhTERT cells and 1.7 M CDDP and 1 nM ET-743 for ϪhTERT cells. To evaluate cell colony-forming ability, aliquots of cell suspension from each sample were seeded into 60-mm Petri dishes with complete medium and incubated for 10 to 12 days. Colonies were stained with 2% methylene blue in 95% ethanol and counted (1 colony Ն 50 cells). Surviving fractions were calculated as the ratio of absolute survival of the treated sample to the absolute survival of the control sample. All of the experiments were repeated four times in triplicate.
Western Blot. Western blot and detection were performed as reported previously (Biroccio et al., 2001) . Briefly, 40 g of total proteins were loaded on denaturing SDS-polyacrylamide gel electrophoresis. Immunodetection of the c-Myc protein was performed using a 1:1000 dilution of the anti-c-myc monoclonal antibody clone 9E10 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). To determine the amount of protein transferred onto nitrocellulose membrane, ␤-actin was used as control. The relative amounts of the transferred proteins were quantified by scanning the autoradiographic films with a gel densitometer scanner (Bio-Rad, Milan, Italy) and normalized to the related ␤-actin amounts.
Cytogenetic Analysis. To obtain chromosome preparation, cells, in the log phase of growth, were incubated with 0.1 g/ml of colcemid for 1 h and trypsinized, and then they were incubated with hypotonic 0.075 M KCl for 20 min, fixed with methanol to acetic acid (3:1, v/v), dropped onto frosted microscope slides, and air-dried overnight. Chromosome aberration frequency was evaluated in at least 50 Giemsa-stained metaphases from two simultaneously grown cultures for each line and each treatment (7 M of CDDP for 2 h and 20 nM ET-743 for 1 h). For all of the experiments, metaphase preparations of the different cells were performed simultaneously under the same conditions. The 2 test was used for statistical analysis.
Bromodeoxyuridine Labeling. Progression of cells through the cell-cycle phase was analyzed by flow cytometry (BD Biosciences, San Jose, CA) using bromodeoxyuridine (BrdU; BD Biosciences) incorporation, as described previously (Biroccio et al., 2001) . Briefly, cells were pulsed with BrdU (10 M for 15 min) 24 h after the end of CDDP and ET-743 treatments. At the end of BrdU pulse and at 4 h intervals after the pulse, the cells were fixed and the DNA was denatured. Cells were then incubated with 2 g/ml of mouse anti-BrdU (clone BMC 9318, Roche Diagnostics, Indianapolis, IN) for 30 min at room temperature, and the BrdUpositive cells were revealed with fluorescein isothiocyanate-conjugated anti-mouse monoclonal antibody (1:20; DAKO, Glostrup, Denmark). To evaluate the percentage of cells in each phase of the cell cycle after propidium iodide staining (1 g/ml), the fraction of BrdU-positive cells was divided into three regions by their DNA content (G 1 , S, and G 2 /M). The three compartments were chosen for each cell line at the end of the pulse and were left unchanged during the following intervals of the analysis.
Detection of Apoptosis. Apoptotic cells were detected by using the FlowTACS in situ terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL)-based Apoptosis Detection Kit (R & D Systems, Minneapolis, MN) according to the manufacturer's instruction. Briefly, 2 ϫ 10 6 cells were collected 48 h after the treatments with equitoxic doses of CDDP and ET-743, fixed with 3.7% formaldehyde/phosphate-buffered saline, washed with phosphate-buffered saline, and permeabilized with 100 l of Cytonin (Trevigen, Gaithersburg, MD) for 30 min at room temperature. The fragmented DNA was revealed by incubating the samples with the labeling reaction mix for 1 h at 37°C, and the fluorescein isothiocyanate-labeled cells were then stained with 50 g/ml propidium iodide solution containing 750 g/ml RNAase for 30 min at room temperature and in the dark. The flow-cytometric analysis was performed using FACSCalibur (BD Biosciences).
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Results
Reconstitution of hTERT Decreases CDDP and ET-743 Sensitivity. In this study, an experimental model obtained previously by our group was used (Biroccio et al., 2002) . Briefly, we first generated M14-derived c-Myc lowexpressing clones (MAS51 and MAS53), characterized by the reduction of hTERT expression, telomerase activity, and telomere shortening compared with the parental line (Biroccio et al., 2001 ). Second, telomerase activity was restored in the c-Myc low-expressing clones (Biroccio et al., 2002) by infection with amphotropic viruses, encoding either hTERT (ϩhTERT cells) or the puromycin resistance only (ϪhTERT cells).
In this article, ϩhTERT cells after 14 (MAS51/T 14 , MAS53/ T 14 ) and 35 PD (MAS51/T 35 , MAS53/T 35 ) and the ϪhTERT cells after 35 PD (MAS51/V 35 , MAS53/V 35 ) after infection were used to study the role of telomerase function on drug sensitivity. Figure 1 shows the survival curves of the different clones exposed to increasing doses of CDDP and ET-743, two DNA-interacting drugs that invariably cause an arrest in G 2 /M phase, and LND, a mitochondria-targeting drug, inducing a G 1 block (Del Bufalo et al., 1996) . No difference in cell survival was observed between ϪhTERT and ϩhTERT cells treated with LND. On the contrary, the survival curves of the ϪhTERT cells treated with CDDP and ET-743 showed an exponential decrease in cell survival with the increasing of doses and, at the highest drug concentrations, the curves decreased in the third decade, reaching values of approximately 0.1%. Reconstitution of hTERT decreased sensitivity to CDDP and ET-743 at all the doses of drugs used. The behavior of the survival curves was biphasic, characterized by a shoulder region followed by an exponential phase at the highest doses, even though the surviving fraction remained between the first and the second decade. The degree of sensitivity to both drugs was strictly associated with the PD of the ϩhTERT cells. In fact, at 7 M CDDP, the surviving fraction of the ϩhTERT cells was approximately 20% after 14 PD and 60% after 35 PD. Similarly, at 20 nM ET-743, the surviving fraction of the ϩhTERT cells was approximately 15% after 14 PD and 50% after 35 PD. Moreover, after 35 PD, the sensitivity to both drugs was superimposable to that of the M14 parental line. To exclude the possibility that the decreased CDDP and ET-743 sensitivity observed in ϩhTERT cells with the increasing PD was caused by a reactivation of c-Myc expression, Western blot analysis was performed. As shown in Fig. 2 , no difference in c-Myc protein expression was evident between ϪhTERT and ϩhTERT cells, as well as between ϩhTERT cells at different PD.
Because hTERT expression levels and telomerase activity did not change in the ϩhTERT cells with the PD increasing (Biroccio et al., 2002) , to explain the difference in drug sensitivity, telomere status was analyzed. Data reported in Ta and 35 (MAS51/T 35 ) PD, showing the maximum number of telomeric fusions per metaphase observed (four, three, and two, respectively), is shown in Fig. 3 .
Reconstitution of hTERT Enables the Cells to Recover from CDDP and ET-743-Induced Damage. We next analyzed the ability of cells to recover from CDDP and ET-743-induced damage. The experiments were performed by using ϪhTERT (MAS51/V 35 ) and ϩhTERT (MAS51/T 35 ) cells after 35 PD after infection treated with equitoxic doses of both drugs, chosen from the dose-response curves (see Fig.  1 ). The doses of 7 M CDDP for ϩhTERT and M14 cells and 1.7 M for ϪhTERT cells that reduced cell survival by approximately 50% (IC 50 ) were used. Figure 4 shows that immediately after the end of CDDP treatment, a similar behavior between the survival curves of ϪhTERT and ϩhTERT was observed. However, a different ability to recover from CDDP damage was evident. In fact, at 96 h, the surviving fraction of ϪhTERT cells was approximately 50%. On the contrary, ϩhTERT cells showed a surviving fraction of approximately 100%, indicating that these cells were able to completely recover from CDDP-induced damage. The doses of ET-743, corresponding to IC 50 , were 20 nM for the ϩhTERT and M14 cells and 1 nM for the ϪhTERT cells. After a decrease of cell survival by approximately 70%, a plateau phase in the ϪhTERT cells was observed, indicating that they were unable to recover from the ET-743-induced damage. On the contrary, the survival fraction of ϩhTERT cells reached approximately 80% of cell survival at 96 h. The survival curves of the ϩhTERT cells treated with both drugs were superimposable to those of M14 cells.
The ability of different cells to recover the damage elicited by CDDP and ET-743 was also evaluated in terms of chromosome damage. Figure 5 shows the distribution of chromosome damage observed from 24 to 96 h after treatment with both drugs. The data showed that the treatment with CDDP or ET-743 significantly (p Ͻ 0.001) enhanced telomeric fusion frequency both in ϪhTERT and in ϩhTERT cells. In addition, both ϪhTERT and ϩhTERT cells treated with CDDP or ET-743 exhibited various chromosome aberrations such as aspecific chromatid and chromosome breaks and exchange figures involving two or more chromosomes. During the time after the treatment, the rate of induced chromosome damage significantly (p Ͻ 0.01) decreased in ϩhTERT cells, whereas no significant difference was observed in ϪhTERT cells. The results obtained when using the MAS51 clone, with and without hTERT reconstitution, were similar to those obtained with the MAS53 clone (data not shown).
Reconstitution of hTERT Enables the Cells to Recover from CDDP and ET-743-Induced G 2 /M Block. To evaluate whether the inability to recover the drug damage elicited by the ϪhTERT cells was related to alterations in cell-cycle progression, BrdU incorporation assay was performed. Figure 6 shows the bivariate DNA/BrdU distribution, performed at different times after 15 min of BrdU labeling, in ϪhTERT (MAS51/V 35 ), ϩhTERT (MAS51/T 35 ), and M14 cells untreated or treated with CDDP and ET-743 at equitoxic doses. It is evident that both drugs caused a similar block in the S-G 2 /M phase of cell cycle 24 h after the end of treatments (0 h), regardless of hTERT expression. However, a significant difference among the lines was observed during the progression through the cell-cycle phases. In fact, although the ϩhTERT cells were able to recover from the CDDP and ET-743-induced block to the same extent as M14 cells, a strong perturbation of the cell cycle was still evident in the ϪhTERT cells 16 h after labeling. This effect was mainly caused by a different progression through the cell cycle between ϪhTERT and ϩhTERT cells. In fact, the analysis of the percentage of BrdU-positive cells in the different phases of cell cycle (Fig. 7) demonstrated that ϪhTERT cells remained in the G 2 /M phase for a prolonged time with respect to ϩhTERT or M14 cells, thus causing a delay in the repopulation of the G 1 and S phases. As a consequence, the CDDP and ET-743-induced G 2 /M block was irreversible in the ϪhTERT cells, in which approximately 80% of BrdUpositive cells were still arrested in G 2 /M. On the contrary, the restored progression into cell cycle in the ϩhTERT cells permitted them to overcome the drug-induced G 2 /M block, as observed in the M14 parental line.
To determine whether the permanence in the G 2 /M phase of CDDP-and ET-743-treated ϪhTERT cells led them to activate the apoptotic program, a TUNEL assay was carried out by flow cytometry, in which the fragmented DNA is simultaneously analyzed with DNA content. Two-parameter flow-cytometry analysis (Fig. 8) demonstrated that the ϪhTERT cells treated with both drugs gave a TUNEL-positive signal in the G 2 /M-phase region (approximately 20%), whereas no apoptotic cells were detected in either the ϩhTERT or M14 cells. Therefore, it follows that CDDP and ET-743 treatments induced DNA fragmentation in the G 2 /M phase in the ϪhTERT cells only, suggesting that the prolonged permanence in G 2 /M of the ϪhTERT cells was responsible for the CDDP and ET-743 sensitivity.
The progression through the cell cycle and the induction of apoptosis obtained by using the MAS51 clone, with and without hTERT reconstitution, were similar to those obtained with the MAS53 clone (data not shown).
Discussion
We report that the reconstitution of telomerase activity was able to modify the functional status of telomeres. In fact, the ϩhTERT cells showed a number of total end-toend fusions significantly lower than those of the ϪhTERT cells. The improved telomere function gradually occurred with the increase of population doublings. The restored telomere function rendered the cells less sensitive to CDDP and ET-743 without affecting LND susceptibility. In particular, ϪhTERT cells containing dysfunctional telomeres were more sensitive to CDDP and ET-743 than were ϩhTERT cells possessing functional telomeres. Moreover, we demonstrated that telomere dysfunction, rather than telomerase activity, determined the chemosensitivity. In fact, by using ϩhTERT cells at two different population doublings showing the same level of telomerase activity (Biroccio et al., 2002) but different telomere status, we demonstrated that the degree of chemosensitivity strictly depended on the severity of telomere dysfunction. Our results are in agreement with the data reported by DePinho et al., demonstrating that telomere dysfunction alters the radio-and chemotherapeutic profile of cells derived from telomerase RNA-null mice (Wong et al., 2000 ; BrdU was added 24 h after the end of CDDP and ET-743 treatment, and cytofluorometric analysis was performed at the end of the 15-min pulse with BrdU (0 h) and from 4 to 16 h after the end of the pulse. A representative of three independent experiments with similar results is shown. Lee et al., 2001) . On the other hand, attenuation of telomerase activity without telomere shortening does not increase sensitivity to anticancer agents (Folini et al., 2000) .
The decreased sensitivity to CDDP and ET-743 after reactivation of telomerase function was caused by the ability of cells to recover from drug-induced damage in terms of cell survival. Similarly, the persistence of structural chromosomal lesions was evident only in ϪhTERT cells treated with both drugs, whereas these aberrations were largely resolved in ϩhTERT cells. The ability of the ϩhTERT cells to recover from drug-induced damage was attributable to the restored cell cycle progression. In fact, although the ϪhTERT cells remained for a prolonged time in the G 2 /M phase with a delay in the repopulation of the G 1 and S phases, hTERT reconstitution restored normal cell cycle. The delayed progression of the G 2 /M phase, observed in ϪhTERT cells, rendered irreversible the S-G 2 /M block induced by both drugs. In fact, at equitoxic doses, both drugs caused a similar arrest of the S-G 2 /M phases, which is recovered only in ϩhTERT cells, although a strong perturbation of the cell cycle was evident in the cells without hTERT reconstitution. Our data are strengthened by the use of the G 1 -blocking drug LND, because the susceptibility to this compound was similar in all the cell lines regardless of hTERT expression and telomere dysfunction. The decreased drug sensitivity was mainly caused by telomere dysfunction rather than by telomerase activity per se, because, as we demonstrated previously, the mutant biologically inactive hTERT, which is catalytically active but unable to maintain telomeres, was unable to restore cell cycle (Biroccio et al., 2002) .
The cell cycle deregulation after alteration of telomere function has been reported by other authors. In particular, the expression of mutant telomerase in immortal telomerase-negative human cells results in chromosome fusion and abnormal cell cycle, with the ratio between the percentage of cells in G 1 and G 2 /M being decreased (Guiducci , 2001) . Similar cell cycle deregulation has been reported by altering the expression of telomere functionregulating proteins, such as Pin2/TRF1 (Shen et al., 1997) , or the new Pin2/TRF1-interacting protein PinX1 (Zhou and Lu, 2001 ).
However, even if an alteration in the cell cycle after telomere dysfunction has already been described, it has not been correlated with drug sensitivity. We demonstrated that the permanence in G 2 /M phase of CDDP-and ET-743-treated cells without hTERT reconstitution led the cells to activate the apoptotic program. Apoptosis was observed only in ϪhTERT cells treated with both drugs and, by using a twoparameter flow-cytometric analysis, we demonstrated that apoptosis occurred at the G 2 /M phase of cell cycle, strengthening the hypothesis that irreversible G 2 /M block induced by treatment was responsible for the CDDP and ET-743 sensitivity.
To the best of our knowledge, this is the first evidence demonstrating that telomere dysfunction is involved in the susceptibility to CDDP and ET-743 in melanoma cells. Therefore, on the basis of previous results demonstrating the efficacy of telomerase inhibitors in cells with short telomeres (Kelland, 2001 ) and recent evidence showing the antitumoral activity of CDDP and ET-743 combination in several histotypes, including melanoma (D'Incalci et al., 2002) , a new approach consisting of the use of telomerase inhibitors able to induce telomere dysfunction, followed by CDDP/ET-743 treatment, could improve the chemotherapeutic response of melanoma.
